They performed a retrospective cohort study between 2006-2017 in patients with cTanyN1-3M0 disease. A total of 120 patients were identified, 30% had lymph node biopsy and 65% of those has biopsy positive disease all of which underwent chemotherapy. Overall survival improved with T1 or less and node negative disease, however, no difference was noted according to biopsy status. In conclusion, the clinical false positive rate may be 1/3 and these findings support further research in a clinical trial.
Presented by: Amy H. Lim, MD, PhD, Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas
Written by: Stephen B. Williams, MD, Medical Director for High Value Care; Chief of Urology, Associate Professor, Director of Urologic Oncology, Director Urologic Research, The University of Texas Medical Branch at Galveston, TX and Ashish M. Kamat, MD, Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 2019 Bladder Cancer Advocacy Network (BCAN) Think Tank August 8-10, 2019 - the Capital Hilton, Washington, DC, USA